Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 page 6 Key metrics page 7 page 8 Outlook 2026 page 9 Disclaimer Copyright by Fresenius Medical Care AG email: ir@freseniusmedicalcare.com phone: +49 6172 609 2525 Revenue development by segment Reconciliation results excl. special items This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG does not undertake any responsibility to update the forward-looking statements in this release. Rounding adjustments applied to individual numbers and percentages may result in these figures differing immaterially from their absolute values. Furthermore, totals and subtotals in tables may differ slightly from unrounded figures due to rounding in accordance with commercial rounding conventions. Fresenius Medical Care AG August 3, 2026 COMPLETE OVERVIEW OF THE SECOND QUARTER AND FIRST HALF YEAR 2026 Investor Relations

Statement of earnings in € million, except share data, unaudited 2026 2025 Change Change at cc 2026 2025 Change Change at cc Total revenue 4,861 4,792 1.4% 3.6% 9,473 9,673 -2.1% 3.3% Costs of revenue 3,551 3,577 -0.7% 1.3% 6,983 7,275 -4.0% 1.5% Selling, general and administrative expense 736 792 -7.1% -5.8% 1,485 1,543 -3.7% 0.8% Research and development expense 40 38 4.0% 4.9% 78 82 -4.5% -1.7% (Income) loss from equity method investees 41 (45) n.a. n.a. 0 (93) -99.9% -99.9% Other operating income (208) (343) -39.5% -39.3% (366) (484) -24.4% -23.5% Other operating expense 235 348 -32.3% -33.5% 541 593 -9.1% -6.3% Operating income 466 425 9.5% 15.3% 752 757 -0.6% 4.6% Operating income excl. special items 1 569 476 19.6% 23.5% 1,036 933 11.1% 16.8% Interest income (15) (22) -32.7% -33.5% (29) (37) -20.4% -19.3% Interest expense 98 97 1.0% 2.0% 191 192 -0.7% 3.6% Interest expense, net 83 75 10.9% 12.3% 162 155 3.9% 9.0% Income before income taxes 383 350 9.3% 15.9% 590 602 -1.8% 3.4% Income tax expense 90 78 14.8% 22.2% 133 139 -4.8% -0.1% Net income 293 272 7.7% 14.1% 457 463 -0.9% 4.5% Net income attributable to noncontrolling interests 75 47 59.0% 65.6% 121 87 42.9% 52.6% Net income attributable to shareholders of FME AG 218 225 -3.1% 3.4% 336 376 -10.8% -6.4% Net income attributable to shareholders of FME AG excl. special items 1 303 268 13.1% 16.8% 553 514 7.6% 12.8% Weighted average number of shares 268,438,292 293,413,449 271,823,512 293,413,449 Basic earnings per share €0.81 €0.77 6.0% 13.0% €1.24 €1.28 -3.7% 1.0% Basic earnings per ADS €0.41 €0.38 6.0% 13.0% €0.62 €0.64 -3.7% 1.0% Operating income 466 425 9.5% 15.3% 752 757 -0.6% 4.6% Depreciation, amortization and impairment loss 363 376 -3.2% -2.7% 826 769 7.3% 13.0% EBITDA 829 801 3.6% 6.8% 1,578 1,526 3.4% 8.8% In percent of revenue Operating income margin 9.6% 8.9% 7.9% 7.8% Operating income margin excl. special items 1 11.7% 9.9% 10.9% 9.6% EBITDA margin 17.1% 16.7% 16.7% 15.8% EBITDA margin excl. special items 1 18.9% 17.5% 18.4% 17.4% 1 For a reconciliation of special items, please refer to the table on page 8. Three months ended June 30, Six months ended June 30, Statement of earnings page 2 of 9 August 3, 2026

Segment information unaudited 2026 2025 Change Change at cc 2026 2025 Change Change at cc Total Revenue in € million 4,861 4,792 1.4% 3.6% 9,473 9,673 -2.1% 3.3% Operating income in € million 466 425 9.5% 15.3% 752 757 -0.6% 4.6% Operating income in € million excl. special items 1 569 476 19.6% 23.5% 1,036 933 11.1% 16.8% Operating income margin 9.6% 8.9% 7.9% 7.8% Operating income margin excl. special items 1 11.7% 9.9% 10.9% 9.6% Days sales outstanding (DSO) 2 60 63 Employees (headcount) 107,226 112,445 Care Delivery segment Revenue in € million 3,478 3,381 2.9% 5.5% 6,772 6,828 -0.8% 5.2% Operating income in € million 435 346 25.6% 33.1% 706 666 6.0% 15.8% Operating income in € million excl. special items 1 527 378 39.5% 45.3% 924 734 26.0% 36.1% Operating income margin 12.5% 10.2% 10.4% 9.8% Operating income margin excl. special items 1 15.1% 11.2% 13.6% 10.7% Days sales outstanding (DSO) 2 57 58 Value-Based Care segment Revenue in € million 536 506 6.0% 9.0% 1,027 1,035 -0.8% 5.9% Operating income in € million 17 (9) n.a. n.a. 6 (6) n.a. n.a. Operating income in € million excl. special items 1 18 (9) n.a. n.a. 26 (5) n.a. n.a. Operating income margin 3.2% -1.7% 0.6% -0.5% Operating income margin excl. special items 1 3.3% -1.7% 2.6% -0.5% Days sales outstanding (DSO) 2 31 29 Care Enablement segment Revenue in € million 1,371 1,348 1.7% 2.7% 2,670 2,715 -1.6% 1.9% Operating income in € million 99 89 10.8% 12.3% 186 183 1.4% 1.5% Operating income in € million excl. special items 1 111 117 -5.5% -4.8% 224 231 -3.3% -2.4% Operating income margin 7.2% 6.6% 7.0% 6.8% Operating income margin excl. special items 1 8.1% 8.7% 8.4% 8.5% Days sales outstanding (DSO) 2 86 92 Inter-segment eliminations 3 Revenue in € million (524) (443) 18.6% 21.4% (996) (905) 10.1% 16.5% Operating income in € million (39) (8) 367.3% 386.4% (61) (12) 342.5% 371.7% Operating income in € million excl. special items 1 (39) (8) 367.3% 386.4% (61) (12) 342.5% 371.7% Corporate Operating income in € million (46) 7 n.a. n.a. (85) (74) 16.1% 47.2% Operating income in € million excl. special items 1 (48) (2) 3338.5% 3580.6% (77) (15) 465.0% 621.8% 2 Includes receivables related to assets held for sale. 3 Services provided by the Care Delivery segment in the U.S. for patients managed under the Value-Based Care segment are provided at fair market value. The Company also transfers products from the Care Enablement segment to the Care Delivery segment at fair market value. The associated internal revenues and expenses and all other consolidation of transactions are included within “Inter-segment eliminations.” cc = constant currency. Changes in revenue, operating income and net income attributable to shareholders of FME AG include the impact of changes in foreign currency exchange rates. We calculate and present these financial measures using both IFRS Accounting Standards and at constant exchange rates to show changes in these metrics and other items without giving effect to period-to-period currency fluctuations. Under IFRS Accounting Standards, amounts received in local (non-euro) currency are translated into euro at the average exchange rate for the period presented. Once we translate the local currency for the constant currency, we then calculate the change, as a percentage, of the current period using the prior period exchange rates versus the prior period. The single quarter results are calculated as the variance between the current year-to-date results less the preceding quarter’s year-to-date which makes the single quarter subject to further foreign exchange fluctuation. This resulting percentage is a non-IFRS measure referring to a change as a percentage at constant currency. These currency-adjusted financial measures are identifiable by the designated term "Constant Currency." 1 For a reconciliation of special items, please refer to the table on page 8. Three months ended June 30, Six months ended June 30, Segment information page 3 of 9 August 3, 2026

Balance sheet in € million, except for net leverage ratio, unaudited June 30, December 31, 2026 2025 Assets Cash and cash equivalents 1,061 1,599 Trade accounts and other receivables from unrelated parties 3,350 3,142 Inventories 2,332 2,141 Other current assets 946 1,016 Goodwill and intangible assets 15,248 14,826 Right-of-use assets 2,889 3,014 Other non-current assets 5,467 5,264 Total assets 31,293 31,002 Liabilities and equity Accounts payable to unrelated parties 810 738 Other current liabilities 6,368 5,507 Non-current liabilities 10,584 10,474 Total equity 13,531 14,283 Total liabilities and equity 31,293 31,002 Equity/assets ratio 43% 46% Debt and lease liabilities Short-term debt 1,741 1,613 Long-term debt, less current portion 5,825 5,692 Current portion of lease liabilities 584 584 Lease liabilities, less current portion 2,813 2,906 Total debt and lease liabilities 10,963 10,795 Minus: Cash and cash equivalents (1,061) (1,599) Total net debt and lease liabilities 9,902 9,196 Reconciliation of annualized adjusted EBITDA and net leverage ratio to the most directly comparable IFRS Accounting Standards financial measure Net income 1,187 1,191 Income tax expense 314 321 Interest income (62) (70) Interest expense 383 385 Depreciation and amortization 1,430 1,463 Adjustments 1 539 447 Annualized adjusted EBITDA 3,791 3,737 Net leverage ratio 2.6 2.5 1 Acquisitions and divestitures made for the last twelve months with a purchase price above a €50 M threshold as defined in the Syndicated Credit Facility (2026: -€1 M; 2025: €1 M), non-cash charges, primarily related to pension expense (2026: €44 M; 2025: €47 M), impairment loss (2026: €127M; 2025: €37 M), and special items, including costs related to the FME25+ Program (2026: €193 M; 2025: €185 M), Legacy Portfolio Optimization (2026: €82 M; 2025: €83 M), Legal Form Conversion Costs (2026: €2 M; 2025: €4 M), Humacyte Remeasurements (2026: €21 M; 2025: €90 M) and Tavneos Impacts (2026: €71 M). Balance sheet page 4 of 9 August 3, 2026

Cash flow statement in € million, unaudited 2026 2025 2026 2025 Operating activities Net income 293 272 457 463 Depreciation, amortization and impairment loss 363 376 826 769 Change in trade accounts and other receivables from unrelated parties 252 194 (134) (113) Change in inventories (17) (16) (164) (87) Change in other assets and liabilities and non-cash items (31) (51) 102 (94) Net cash provided by (used in) operating activities 860 775 1,087 938 In percent of revenue 17.7% 16.2% 11.5% 9.7% Investing activities Purchases of property, plant and equipment and capitalized development costs (240) (154) (430) (300) Proceeds from sale of property, plant and equipment 5 7 8 11 Capital expenditures, net (235) (147) (422) (289) Free cash flow 625 628 665 649 In percent of revenue 12.9% 13.1% 7.0% 6.7% Acquisitions and investments, net of cash acquired, and purchases of intangible assets (2) (9) (7) (15) Investments in debt securities (74) 0 (74) (11) Proceeds from divestitures, net of cash disposed (1) 1 1 20 Proceeds from sale of debt securities 42 13 62 45 Free cash flow after investing activities 590 633 647 688 Three months ended June 30, Six months ended June 30, Cash flow page 5 of 9 August 3, 2026

in € million, unaudited 2026 2025 Change Change at cc Organic growth Same market treatment growth 1 Three months ended June 30, Total revenue 4,861 4,792 1.4% 3.6% 4.9% Care Delivery segment 3,478 3,381 2.9% 5.5% 7.4% -0.4% Thereof: U.S. 2,897 2,817 2.8% 5.5% 6.7% -0.9% Thereof: International 581 564 3.2% 5.3% 11.2% 0.8% Value-Based Care segment 536 506 6.0% 9.0% 9.0% Care Enablement segment 1,371 1,348 1.7% 2.7% 2.7% Inter-segment eliminations (524) (443) 18.6% 21.4% Thereof: Care Delivery segment (137) (118) 17.3% 20.8% Thereof: Care Enablement segment (387) (325) 19.1% 21.7% Six months ended June 30, Total revenue 9,473 9,673 -2.1% 3.3% 4.4% Care Delivery segment 6,772 6,828 -0.8% 5.2% 6.8% -0.1% Thereof: U.S. 5,662 5,709 -0.8% 6.0% 6.7% -0.6% Thereof: International 1,110 1,119 -0.8% 1.6% 7.3% 1.1% Value-Based Care segment 1,027 1,035 -0.8% 5.9% 5.9% Care Enablement segment 2,670 2,715 -1.6% 1.9% 1.9% Inter-segment eliminations (996) (905) 10.1% 16.5% Thereof: Care Delivery segment (259) (238) 9.4% 16.8% Thereof: Care Enablement segment (737) (667) 10.4% 16.3% 1 Same market treatment growth = organic growth less price effects Revenue development by segment Revenue development by segment page 6 of 9 August 3, 2026

unaudited 2026 2025 Change 2026 2025 Change 2026 2025 Change Care Delivery segment 3,513 3,676 -4% 289,610 300,339 -4% 21,521,790 22,314,266 -4% Thereof: U.S. 2,539 2,627 -3% 203,177 206,259 -1% 15,150,505 15,327,129 -1% Thereof: International 974 1,049 -7% 86,433 94,080 -8% 6,371,285 6,987,137 -9% unaudited 2026 2025 Change 2026 2025 Change Value-Based Care segment Total U.S. 927,045 869,968 7% 154,349 147,532 5% Six months ended June 30, Member Months Membership Key metrics Six months ended June 30, Clinics Patients Treatments Key metrics page 7 of 9 August 3, 2026

in € million, except share data, unaudited Results 2026 FME25+ Program Legacy Portfolio Optimiza-tion1 Humacyte Remeasure-ments Tavneos Impacts2 Sum of special items Results 2026 excl. special items Currency translation effects Results 2026 excl. special items at cc Results 2025 FME25+ Program Legacy Portfolio Optimiza-tion1 Legal Form Conversion Costs Humacyte Remeasure-ments Sum of special items Results 2025 excl. special items Change excl. special items Change excl. special items at cc Three months ended June 30, Total revenue 4,861 — — — — — 4,861 104 4,965 4,792 — — — — — 4,792 1.4% 3.6% Care Delivery segment 3,478 — — — — — 3,478 88 3,566 3,381 — — — — — 3,381 2.9% 5.5% Thereof: U.S. 2,897 — — — — — 2,897 76 2,973 2,817 — — — — — 2,817 2.8% 5.5% Thereof: International 581 — — — — — 581 12 593 564 — — — — — 564 3.2% 5.3% Value-Based Care segment 536 — — — — — 536 15 551 506 — — — — — 506 6.0% 9.0% Care Enablement segment 1,371 — — — — — 1,371 14 1,385 1,348 — — — — — 1,348 1.7% 2.7% Inter-segment eliminations (524) — — — — — (524) (13) (537) (443) — — — — — (443) 18.6% 21.4% EBITDA 829 24 3 (7) 71 91 920 24 944 801 49 (2) 1 (9) 39 840 9.5% 12.3% Total operating income 466 42 (3) (7) 71 103 569 19 588 425 53 6 1 (9) 51 476 19.6% 23.5% Care Delivery segment 435 26 (5) — 71 92 527 21 548 346 26 6 — — 32 378 39.5% 45.3% Value-Based Care segment 17 1 — — — 1 18 1 19 (9) 0 — — — 0 (9) n.a. n.a. Care Enablement segment 99 15 0 (3) — 12 111 0 111 89 27 0 — 1 28 117 -5.5% -4.8% Inter-segment eliminations (39) — — — — — (39) (2) (41) (8) — — — — — (8) 367.3% 386.4% Corporate (46) 0 2 (4) — (2) (48) (1) (49) 7 0 — 1 (10) (9) (2) 3338.5% 3580.6% Interest expense, net 83 — — — — — 83 1 84 75 — — — — — 75 10.9% 12.3% Income tax expense 90 11 6 (3) 4 18 108 6 114 78 14 (4) 0 (2) 8 86 25.9% 30.9% Net income attributable to noncontrolling interests 75 — — — — — 75 2 77 47 — — — — — 47 59.0% 65.6% Net income3 218 31 (9) (4) 67 85 303 10 313 225 39 10 1 (7) 43 268 13.1% 16.8% Basic earnings per share €0.81 €0.12 €(0.03) €(0.02) €0.25 €0.32 €1.13 €0.03 €1.16 €0.77 €0.13 €0.03 €0.00 €(0.02) €0.14 €0.91 23.6% 27.7% Six months ended June 30, Total revenue 9,473 — — — — — 9,473 523 9,996 9,673 — — — — — 9,673 -2.1% 3.3% Care Delivery segment 6,772 — — — — — 6,772 414 7,186 6,828 — — — — — 6,828 -0.8% 5.2% Thereof: U.S. 5,662 — — — — — 5,662 387 6,049 5,709 — — — — — 5,709 -0.8% 6.0% Thereof: International 1,110 — — — — — 1,110 27 1,137 1,119 — — — — — 1,119 -0.8% 1.6% Value-Based Care segment 1,027 — — — — — 1,027 70 1,097 1,035 — — — — — 1,035 -0.8% 5.9% Care Enablement segment 2,670 — — — — — 2,670 97 2,767 2,715 — — — — — 2,715 -1.6% 1.9% Inter-segment eliminations (996) — — — — — (996) (58) (1,054) (905) — — — — — (905) 10.1% 16.5% EBITDA 1,578 85 14 (4) 71 166 1,744 88 1,832 1,526 77 16 1 65 159 1,685 3.5% 8.7% Total operating income 752 208 9 (4) 71 284 1,036 53 1,089 757 80 30 1 65 176 933 11.1% 16.8% Care Delivery segment 706 144 3 — 71 218 924 75 999 666 40 28 — — 68 734 26.0% 36.1% Value-Based Care segment 6 20 — — — 20 26 2 28 (6) 1 — — — 1 (5) n.a. n.a. Care Enablement segment 186 44 1 (7) — 38 224 2 226 183 38 2 — 8 48 231 -3.3% -2.4% Inter-segment eliminations (61) — — — — — (61) (4) (65) (12) — — — — — (12) 342.5% 371.7% Corporate (85) 0 5 3 — 8 (77) (22) (99) (74) 1 — 1 57 59 (15) 465.0% 621.8% Interest expense, net 162 — — — — — 162 7 169 155 — — — — — 155 3.9% 9.0% Income tax expense 133 53 11 (1) 4 67 200 10 210 139 21 1 0 16 38 177 12.2% 17.8% Net income attributable to noncontrolling interests 121 — — — — — 121 9 130 87 — — — — — 87 42.9% 52.6% Net income3 336 155 (2) (3) 67 217 553 27 580 376 59 29 1 49 138 514 7.6% 12.8% Basic earnings per share €1.24 €0.57 €(0.01) €(0.01) €0.25 €0.80 €2.04 €0.09 €2.13 €1.28 €0.20 €0.10 €0.00 €0.17 €0.47 €1.75 16.2% 21.8% 3 Attributable to shareholders of FME AG. 2 The impacts from the recommended revocation of the TAVNEOS® marketing authorization which led primarily to an impairment of intangible assets recorded by Vifor Fresenius Medical Care Renal Pharma Ltd., resulting in a negative impact on FME AG’s income (loss) from equity method investees. 1 2026: mainly related to costs associated with the 2025 divestiture of select assets of the FME AG’s wholly owned Spectra Laboratories; 2025: mainly related to the proposed divestiture of select assets of FME AG’s wholly owned Spectra Laboratories as well as the proposed divestitures in Brazil, Kazakhstan and Malaysia as well as impairment losses primarily related to right-of-use assets. Special items Reconciliation of non-IFRS financial measures to the most directly comparable IFRS Accounting Standards financial measures for comparability with the Company's outlook Special items Reconciliation results excl. special items page 8 of 9 August 3, 2026

Outlook 2026 Spalte1 Outlook 2026 (at Constant Currency) Results 2025 Revenue growth1 Broadly flat €19,628 M Operating income growth1 Between positive and negative mid-single digit percent €2,212 M 1 Outlook 2026 is based on the assumptions outlined in the earnings release for the fourth quarter and full year of 2025 and excludes special items. Special items include the costs related to the FME25+ Program, the impacts from Legacy Portfolio Optimization, the Humacyte Remeasurements and the Tavneos Impacts as well as other effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of providing the outlook. The outlook assumes current laws, policies, regulations, and tariffs. The growth rates are based on the results 2025 excluding the costs related to the FME25+ Program (€194 M for operating income), the impacts from Legacy Portfolio Optimization (€97 M for operating income), the Legal Form Conversion Costs (€4 M for operating income) and the Humacyte Remeasurements (€90 M for operating income). Outlook 2026 page 9 of 9 August 3, 2026